The impact of anti-inflammatory therapy on intraocular pressure reduction following selective laser trabeculoplasty

Abstract

Background and objective: To determine whether the use of postoperative topical anti-inflammatory therapy affects the intraocular pressure (IOP)-lowering efficacy of selective laser trabeculoplasty in eyes with primary open-angle glaucoma.

Patients and methods: In this prospective, randomized, observer-masked study, 25 participants with primary open-angle glaucoma following bilateral 360 degrees selective laser trabeculoplasty used prednisolone acetate 1% four times daily in one randomly selected eye for 1 week. IOP was assessed at baseline and 1 week, 1 month, and 3 months after selective laser trabeculoplasty.

Results: Baseline IOP and selective laser trabeculoplasty treatment parameters were comparable in both groups. Mean IOP was similar in eyes that did and did not receive steroid therapy at 1 week (17.0 vs 16.3 mm Hg, respectively, P = .613), 1 month (16.8 vs 16.2 mm Hg, respectively; P = .571), and 3 months (16.0 vs 15.8 mm Hg, respectively; P = .819).

Conclusion: A 1-week course of topical prednisolone acetate 1% four times daily did not affect the IOP-lowering effect of selective laser trabeculoplasty in eyes with primary open-angle glaucoma.

Trial registration: ClinicalTrials.gov NCT00406042.